Subjective assessments of research domain criteria constructs in addiction and compulsive disorders: a scoping review protocol

Ana Paula Ribeiro, Marcelo Piquet-Pessôa, Carina Félix-da-Silva, Julia Fernandes Eigenheer Mühlbauer, Juliana B de-Salles-Andrade, Leonardo F Fontenelle

ABSTRACT

Introduction Obsessive-compulsive and related disorders (OCRDs) and disorders due to addictive behaviours (DABs) are prevalent conditions that share behavioural and neurobiological characteristics. The Research Domain Criteria lists a series of constructs whose dysfunctions may be present in both groups of disorders. The present study will describe the research protocol of a scoping review of the literature on self-report scales and questionnaires that tap dysfunctional constructs that underlie OCRDs and DABs.

Methods and analysis This protocol outlines a scoping review on self-report tools and questionnaires that assess OCRDs and DABs-related constructs. The scoping review will select sources in MEDLINE, EMBASE, PsychINFO and Web of Science databases. Inclusion and exclusion criteria will be designed according to the Population, Concept, Context, Types of source framework. Two reviewers will screen independently titles, abstracts and full texts to determine the eligibility of articles. A methodological framework including six stages steps ((1) identifying a research question; (2) identifying relevant studies; (3) study selection; (4) charting the data; (5) collating, summarising and reporting the result) will be used, and the findings will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. Information extracted will be collated, and quantitative results will be presented using descriptive statistics such as percentages, tables, charts and flow diagrams as appropriate.

Ethics and dissemination Ethical approval for conducting this scoping review is not required, as this study will involve secondary analysis of existing literature. The researchers will disseminate the study results via conference presentations and publication in a peer-reviewed journal.

Scoping review protocol registration DOI 10.17605/OSF.IO/9J765.

INTRODUCTION

Psychiatric nosology is constantly evolving to best fit new research knowledge. Current diagnostic systems, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the International Classification of Diseases (ICD), define disorders according to symptoms and syndromes, in which a minimum number of criteria for a given disorder must be met or general features must be identified before diagnoses are made. This approach offers some advantages, as treatment decisions are binary, and clinicians need functional categories for guiding clinical practice. The last edition of the DSM (5th Edition) and ICD-11 (https://icd.who.int/en) attempted to absorb and translate to clinical practice recent advances in neuropsychiatric research. For instance, the creation of an ‘obsessive-compulsive and related disorders’ (OCRD) group and the inclusion of behavioural addictions into a ‘substance and behaviour addictions’ group—or ‘disorders due to substance use or addictive behaviours’ (DABs) section in the ICD-11—reflected new concepts in both compulsive and addiction research. However, there is increasing evidence that diagnostic categories do not fully capture the natural organisation of psychopathology symptoms. The excessive
co-occurrence and similarities between different disorders and the biological heterogeneity within the diagnostic groups hamper the identification of aetiology and pathophysiological mechanisms, thus impeding the identification of underlying neurobiological substrates.

To address this problem, dimensional definitions of transdiagnostic mental health problems have been suggested. The US National Institute of Mental Health Strategic Plan proposed new ways of classifying psychopathology based on dimensions of observable behaviour and neurobiological measures. The Research Domain Criteria (RDoC; www.nimh.nih.gov) defines basic constructs to be studied across multiple units of analysis, from genes to neural circuits to behaviours. The ultimate intention is to translate primary neurobiological and behavioural research results to the clinical domains, thus optimally matching treatments for mental disorders. Contrary to the traditional diagnostic classification system, the goal of this model is to use a data-driven approach to determine constructs that aid in the understanding and classification of mental disorders. It is theorised that such constructs may serve as endophenotypes (intermediate phenotypes): objective, heritable, quantitative traits hypothesised to represent a genetic risk for polygenic disorders at more biologically tractable levels than distal behavioural and clinical phenotypes. Endophenotype models of disease have the potential to help clarify the diagnostic classification and aetiological understanding of complex brain disorders, bridging psychological and neural substrates more naturally and improving targeted treatment interventions. They can also help understand treatment response or resistance across conditions. Previous work has shown that intermediate phenotypes track variation in clinical symptoms across multiple disorders, and can be mapped onto underlying brain structure and function. This transdiagnostic approach is more sensitive to detecting neural correlates in psychiatric patients than conventional case-control comparisons, revealing new insights into psychopathology.

Two endophenotypes of relevance not just in clinical but also at a population level are the tendencies towards impulsive and compulsive behaviours, given their high prevalence in the general population. Normal human behaviour relies on a flexible balance between initiation and inhibition, and abnormalities within these pathways contribute to various maladaptive acts. In this sense, impulsivity and compulsivity have been identified as significant motivating factors for disinhibited and repetitive behaviours. For long conceptualised as representing opposing ends along a spectrum, more recently, however, impulsivity and compulsivity are being seen as orthogonal and overlapping constructs in that they both imply underlying problems with top-down inhibitory control.

On a phenomenological level, impulsivity refers to rigid, repetitive and functionally impairing behaviours characterised by the feeling that one has to perform while being aware that these acts are not in line with one’s overall goal. It is the hallmark of the disorders among the OCRDs group, which includes obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), hoarding disorder, hair-pulling disorder (trichotillomania) and excoriation disorder (compulsive skin-picking). These conditions tend to share repetitive, unwanted thoughts, urges or images and a range of compulsive behaviours, like washing, checking, counting, asking/confessing and ordering, in OCD; mirror checking in BDD; and repetitive hair-pulling or skin-picking in trichotillomania and excoriation disorder, respectively. The decision to group these disorders was based on evidence showing broad similarities in symptom presentation (eg, compulsive/repetitive behaviours) and other clinical validators (eg, shared family history). However, no consensus exists about the scope of the ‘OC spectrum’ and the OCRD chapter in DSM-5 has been controversial.

In its turn, impulsivity is a multifaceted construct with many aspects that can be seen in healthy individuals. However, when accentuated, it confers an increased propensity to many disorders. It has been defined as a trait leading to ‘actions that are poorly conceived, prematurely expressed, overly risky or inappropriate to the situation and often result in undesirable consequences’. While it is considered the pivotal element in so-called ‘impulse control disorders’ (compulsive sexual behaviour, pyromania, kleptomania and intermittent explosive disorder; https://icd.who.int/en), it has been consistently associated with the development of DABs. DABs comprehend behaviours that produce short-term rewards and persist despite their adverse consequences. People with DABs report an urge or craving and anxiety before using the drug of choice (or performing the disturbing behaviour, like gambling), feelings that decrease after the behaviour, following a positive mood state or ‘high’. In contrast to OCRDs, DABs have an ego-syntonic nature, even though they may become ego-dystonic over time.

Despite these differences, keeping those conditions in distinct groups has become a challenge. Advances in research in both compulsive (OCRDs) and impulsive, addictive disorders (DABs) describe several commonalities between them. The repetitive engagement in self-defeating behaviours suggest individuals OCRDs and DABs may exhibit impaired reward and/or punishment processing whereas the diminished ability to stop or divert unwanted ideas and actions indicates the presence of cognitive and behavioural inflexibility. Another aspect is habitual responding and diminished goal-directed control, both suggesting excessive habit-learning. Studies have shown that compulsive behaviours in OCRDs (especially in OCD) may start with anxiety and harm avoidance, but gradually evolve into more habitual or impulsive responses with progression and chronicity. Similarly, it is now recognised that initial (impulsive) drug use may turn into chronic (compulsive) drug-taking that characterised DAB. This progression may be a result of the change from initial action-outcome (reward-based)
learning to stimulus-response (habitual) learning, which is possibly related to imbalances between ventral and dorsal frontostriatal recruitment. Another theory emphasises the transition from positively reinforced drug-taking (impulsive stage) to negatively reinforced (removal of aversive state) compulsive drug-use (compulsive stage). Also, both DABs and OCRDs subjects exhibit reward dysfunction. The involvement of areas of the pre-frontal cortex—especially anterior cingulate cortex, ventromedial prefrontal cortex, dorsolateral prefrontal cortex and orbitofrontal cortex—, thalamus and striatum in functional and neuroimaging studies also reinforce the relevance of top-down cognitive control in both groups.

Thus, although there is evidence that differences exist between OCRDs and DABs, especially in treatment responsiveness, there seems to be enough support for shared vulnerability between those groups, leading some investigators to argue that OCD could be viewed as a form of behavioural addiction. Therefore, a transdiagnostic approach that learns patterns from data in the absence of these group labels (eg, disorder groups) is a promising method for better understanding the conditions among the impulsive-compulsive spectrum.

Recently, experts examined the existing literature to form a unifying consensus framework of biologically validated initiators of DABs and OCRDs. Using a transdiagnostic approach, these recent Delphi reviews endorsed six constructs as essential to understanding addiction: reward valuation, reward prediction error (or expectancy), action selection, reward learning, habit and response inhibition (and selection). As essential or very important to the pathophysiology of OCRDs, three constructs from the RDoC matrix (response selection and inhibition/suppression, performance monitoring and habit) emerged. Compulsivity, not initially listed in the RDoC matrix, was also identified as essential to understanding both categories. Those Delphi reviews reinforce the agreement that there is a strong consensus in the field that crucial processes across the addiction-to-OCR (as so the impulsive-compulsive) spectrum are shared, especially those involving reward.

**Rationale**

As with other RDoC constructs, those domains are frequently evaluated with neuropsychological tests (table 1). Although commonly used in lab research, decision-making tasks have significant limitations. They are impractical in a clinical setting—a comprehensive assessment battery of existing laboratory paradigms for addiction or OCRDs may take several hours. Subjective assessments, like self-reports and questionnaires, are faster to administer, can be undertaken with or without supervision, and provide richer phenomenological data (rather than a single outcome measure) with information on experimentally unobserved behaviours. Additionally, those subjective measures are more strongly related to disordered behaviour than cognitive tests. However, most available instruments focus on characterising symptoms (vs mechanisms)—guided by a descriptive phenomenological approach (DSM-5 criteria)—rather than transdiagnostic constructs. While there has been some work on assessment tools in OCD, there has been no synthesis of the available evidence on appropriate instruments usable in transdiagnostic samples. To address this gap in the literature, a scoping review to examine and map the range of subjective assessment tools in use for addiction and OCRDs is proposed.

**OBJECTIVES**

This paper aims to present the protocol of a scoping review of the literature about self-report scales that address high consensus constructs underlying DABs and OCRDs, as described by Yücel et al. Consistent with the RDoC framework, clinical evaluation of the diagnostic and prognostic value of the constructs identified here is of value for developing transdiagnostic treatment approaches. For instance, studying different aspects of compulsivity and their neural correlations in addiction and OCRDs may help define shared brain networks that can help identify appropriate prevention and treatment targets. A better knowledge of the available instruments will help develop an assessment battery sensitive to the core domains of OCRDs and DABs and will inform future research in the field.

**METHODS AND ANALYSIS**

Among many possible methods for conducting an evidence synthesis study, a scoping review is an appropriate methodology to address measurement tools in the context of transdiagnostic constructs in both DABs and OCRDs. Unlike systematic reviews—which summarise all existing evidence on a specific and similar topic—scoping reviews are broader and more exploratory. It can be used to clarify concepts and definitions within the literature, to identify knowledge gaps and characteristics of a particular theory or concept, especially when a research area is complex or has yet to be comprehensively reviewed.

The present scoping review will use the Arksey and O’Malley framework for conducting scoping reviews, and further refined by the Joanna Briggs Institute, including the six-stage steps: (1) identifying a research question; (2) identifying relevant studies; (3) study selection; (4) charting the data; (5) collating, summarising and reporting the results. The objective of this particular scoping review does not require the sixth step, a consultation stage (optional). We will inform our findings according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist (PRISMA-ScR) (online supplemental file 1).

The aim of the scoping review protocol should be to give a broad overview of currently available tools and present a summary of their nature, similarities and differences.
### Table 1  RDoC high consensus constructs in addiction and OCRDs according to Yücel et al.\textsuperscript{72}

| Constructs | Definition | Behaviour paradigms |
|------------|------------|---------------------|
| Habit | Sequential, repetitive, motor behaviours or cognitive processes elicited by external or internal triggers that, once initiated, can go to completion without continuous effortful oversight. Habits are implicit and efficient, requiring few cognitive resources, but can also be maladaptive under novel circumstances. Some habit-related behaviours could be pathological expressions of processes that under other circumstances subserve adaptive goals. Habits are based on previous positively or negatively reinforced learning and commonly occur after extended learning. Both habit formation and expression are typically operationalised within motor control systems. When habit formation is motivated by reward learning, it overlaps with the habit construct within the positive valence domain. | Devaluation task  
Habit learning task  
Habit task |
| Compulsivity | Additional construct to the RDoC that received endorsement as a primary construct by experts in both Delphi reviews. Compulsivity was delineated as distinct from habit in that it can also be repetitive, or automatic behaviour. However, it is distinct from habit in that it can also be associated with negative outcome expectancy that contributes to the experience of being ‘forced’ or ‘compelled’ to act despite negative consequences, which further distinguishes it from impulsivity (the experience of being ‘driven’ and associated with positive outcome expectancies). | Information sampling task  
Balloon analogue risk task  
Reversal learning  
Intra-dimensional/extra-dimensional  
Fruit task  
Probabilistic reversal learning task set  
Shifting task  
Wisconsin card sorting task |
| Response inhibition | A sub-construct of the cognitive control system that is responsible for operation of cognitive and emotional systems, in the service of goal-directed behaviour. This function is required when prepotent responses (those automatically elicited) are not adequate to meet the demands of the current context or need to be suppressed. Response inhibition has been presented in the literature as a facet of response selection, an executive process where one consciously withholds a response in the service of goal-directed behaviour. | Flanker, Simon, Stroop  
Antisaccade  
Conflicting/contralateral motor response task  
Countermanding  
Go/NoGo  
Motor persistence paradigms  
Stimulus–response incompatibility  
Stop-signal reaction time |
| Performance monitoring | A sub-construct of the cognitive control system, responsible for modulating other cognitive and emotional systems, in the service of goal-directed behaviour, when prepotent modes of responding are not adequate to meet the demands of the current context. Additionally, control processes are engaged in the case of novel contexts, where appropriate responses need to be selected from among competing alternatives and allows feedback learning where behaviour can be adjusted in order to optimise goal-directed behaviour. | Flanker, Simon, Stroop task |
| Reward | Reward valuation: processes by which the probability and benefits of a prospective outcome are computed by reference to external information, social context (e.g., group input) and/or prior experience. This computation is influenced by pre-existing biases, learning, memory, stimulus characteristics and deprivation states. Reward valuation may involve the assignment of incentive salience to stimuli. Reward learning: a type of reinforcement learning by which organisms acquire information about stimuli, actions and contexts that predict positive outcomes, and by which behaviour is modified when a novel reward occurs, or outcomes are better than expected. | ► Reward valuation:  
Delay discounting probability choice task  
Willingness to pay task  
► Expectancy reward prediction error:  
Drifting double bandit Rutledge passive lottery task  
Monetary incentive delay task  
► Reward learning:  
Drifting double bandit  
Pavlovian conditioning  
Cambridge/Iowa gambling task  
Probabilistic reward task  
Probabilistic stimulus selection task  
Value-modulated attentional capture task |
| Action selection preference based decision-making | Processes whereby an individual engages a plan for spatial and temporal components of possible purposeful movements, which match internal and external constraints to achieve a goal. It involves an evaluation of costs/benefits and occurs in the context of multiple potential choices available for decision-making. | Balloon analogue risk task |

Definitions of constructs and their related behaviour paradigms can be found at www.nimh.nih.gov. OCRDs, obsessive-compulsive and related disorders; RDoC, Research Domain Criteria.
In keeping with this aim, no empirical evaluation will be conducted. However, the final review’s data extraction and discussion sections will highlight variations in the target groups of different tools and the scales used.

Methodological framework

Stage 1: identifying the research question

This scoping review will focus on two aspects of the DABs and OCRDs. First, behaviour paradigms widely used to investigate repetitive behaviours in laboratory research have limited use in the clinical setting. Second, self-report questionnaires available for subjective assessment of such behaviours focus mainly on DSM-5 symptoms but rarely assess transdiagnostic constructs. To address these problems, an initial research question has been proposed:

What instruments are currently available for assessing important RDoC constructs in DABs and OCRDs?

The term ‘currently available’ for this scoping review refers to questionnaires published in peer-reviewed journals at any time. As appropriate for this methodology, this research question may be adequate to the literature found by the authors during the research process.

Stage 2: identifying relevant studies

A detailed and comprehensive search will be done to obtain all relevant studies that mention the instruments of interest. We will search for evidence in MEDLINE, EMBASE, PsychINFO and Web of Science databases, including original and review papers and grey literature (conference proceedings, dissertations and theses). An additional hand search in reference lists of selected papers will also be conducted to identify possible additional studies. The detailed inclusion criteria and search strategy were guided using the Population, Concept, Context, and Types of Sources of Evidence strategy described by the JBI Reviewer’s Manual (table 2).

To identify the relevant studies, we adopted the three-step search strategy recommended by the JBI manual in this stage. The first and second steps included a limited search in MEDLINE (via PubMed) to retrieve relevant articles. The title and abstract of selected papers from this initial broad search were scanned for keywords and index terms to describe the articles. In the second step, the keywords and index terms identified in the first step were used to develop the search strategies (search strings) for the final search in all databases (table 3). The third and final step will include the ‘hand-searching’ of the reference list of identified reports and articles for additional sources. The first step of the search was conducted on 1 December 2021, and the selection for full-text reading was concluded on 31 March 2022, due to the high number of papers retrieved. The planned end date for completing the review is 30 September 2022.

All relevant studies recovered from the comprehensive search, irrespective of study design or date of publication, will be selected. A large range of languages will be allowed (including English, Spanish, Portuguese, French, Italian and German), as the purpose of a scoping review is to be as comprehensive as possible.

Only studies reporting transdiagnostic instruments that address RDoC relevant constructs for DABs and OCRDs—as defined previously in both Delphi reviews—will be included in the review. Validation of selected tools in other languages will also be included during the selection stage. Instruments designed to map or assess the severity of specific DSM or ICD defined disorders or that focus on just one symptom or behaviour but are not applicable in a transdiagnostic sample or population—such as Y-BOCS for OCD—are beyond the scope of this review and will not be included. Studies mentioning instruments not validated or without information about validating procedures undertaken, studies that do not have any

| Table 2 Population, Concept, Context and Types of sources of evidence (JBI Reviewer’s Manual) |
|------------------------------------------|
| **Main concept** | **Inclusion criteria** |
| Population | NA |
| Concept | ▶ Instruments/self-reports/tools |
| | ▶ Format (eg, paper or web-based) |
| | ▶ Validity and reliability (ie, if and how they have been psychometrically tested) |
| | ▶ RDoC constructs: contents (ie, assessment domains) of the included instruments |
| Context | Open (sources of evidence from any contextual setting would be eligible for inclusion) |
| Types of sources of evidence | Peer-reviewed publications and grey literature |
| RDoC, Research Domain Criteria. | |
measurement tool, studies describing protocols only and duplicates will be excluded.

**Stage 3: study selection**

After the search, the titles and abstracts of identified records will be imported into a reference manager (Endnote 20, 2022 Clarivate) for deduplication. The selection of studies will involve two stages of screening. Stage 1 will involve the screening of titles and abstracts by two authors independently to determine their eligibility for full-text review based on the a priori inclusion and exclusion criteria. In stage 2, authors will independently assess full-text articles for whether they meet the inclusion or exclusion criteria. If any disagreement occurs in relation to inclusion, both authors will review full-text articles again. In the event of no agreement, a senior expert of the research team (LFF) will discuss the differing opinions until a consensus is reached. The number of studies excluded after screening titles, abstracts and full texts will be recorded, as well as the reasons for exclusion. On study selection, an adapted version of the PRISMA flow diagram will be completed to report final numbers, detailing reasons for exclusion as recommended in the PRISMA-ScR checklist.39

The study selection will be guided by the eligibility criteria specified under the inclusion/exclusion criteria above to ensure that relevant studies are selected.

**Stage 4: charting the data**

A data charting form that will provide a logical summary of information extracted from each full-text article and instrument included in the study will be developed before the scoping review and updated as necessary as the study progresses (table 4). The data charting form will be designed to extract information relevant to the review question and objectives and will include, but may not be limited to, title, publication type, the purpose of the study and methodology, target population, instrument of interest, constructs assessed, number of items, mode of administration, validity and reliability information (box 1). Data charting will be carried out independently by two authors. A senior expert of the research team (LFF) will resolve differing opinions and provide supervisory oversight to the final version of the data extracted.

**Stage 5: collating, summarising and reporting the results**

Data extracted from included studies will be collated, and quantitative results will be presented using descriptive statistics such as percentages and tables, charts and flow diagrams. This will be followed by an informed discussion based on careful consideration of the results in keeping with the purpose and objective of the review. No meta-analysis is planned for the review, and neither will the quality of evidence of included studies be assessed, as the purpose of the scoping review is to give a descriptive overview of currently available measuring tools in the literature and present a summary of the nature, similarities and differences of the instruments found.

**Patient and public involvement**

No patient involved.

**AMENDMENTS**

Any amendments to this protocol will be documented and reported, with details of amendments and rationale for why they occurred.

Ethics approval is not a requirement for the present review. All data will be obtained from publicly available documents, and no primary data will be generated. The

---

**Table 4** Data extraction template

| Study characteristics | Extracted data |
|----------------------|----------------|
| General information  | Reference      |
|                      | Publication type (eg, journal article, grey literature, reports, government document) |
|                      | Purpose of study (eg, validation study, comparison study, intervention study) |
|                      | Methodology     |
|                      | Target population or setting (eg, school/community/clinic) |
| Measurement tools    | Instrument of interest |
|                      | Constructs assessed |
|                      | Number of items  |
|                      | Mode of administration |
|                      | Measurement properties (validity and reliability) |

---

**Box 1 Inclusion and exclusion criteria**

**Inclusion criteria**

- Articles related to DABs and/or OCRDs.
- Articles related to any subconstructs of interest, such as habit, reward, etc.
- Articles presenting any kind of assessment of such constructs.
- Original and review studies, quantitative, qualitative and mixed methods study designs.
- Articles published in English, Spanish, Portuguese, French, Italian and German.
- Papers published at any time.

**Exclusion criteria**

- Articles not related to the main subject.
- Articles related to the subject but only reporting behavioural tasks as measures of the constructs.
- Studies that focus exclusively on neuroimaging.
- Studies mentioning assessments that are specific to one single disorder, that is, not transdiagnostic measures.
- Studies in other languages, such as Turkish or Chinese, for feasibility reasons only.

DABs, disorders due to addictive behaviours; OCRDs, obsessive-compulsive and related disorders.
results of the study will be disseminated through publication in a peer-reviewed journal and presented at relevant conferences.

Contributors APR was responsible for the conception and design of the study, the collection, analysis, and interpretation of data, and the preparation of the manuscript. LFF was responsible for the conception and design of the study, the analysis and interpretation of data, and the preparation of the manuscript. MP-P was involved in the collection, analysis, and interpretation of data and the preparation of the manuscript. CF-JEM and JBdS-A were involved in the collection, analysis, and interpretation of data. All authors revised and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Funding This work forms part of the evidence synthesis phase of a master’s research project. BMJ is supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (#302526/2018-8), Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (RE 26/203.052/2017), the D’Or Institute of Research and Education (no grant number) and the David Winston Turner Endowment Fund (no grant number).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Ana Paula Ribeiro http://orcid.org/0000-0002-0566-3538

REFERENCES
1 American Psychiatric Association. Dsm-5 diagnostic classification. Diagnostic Stat. Man. Ment. Disord 2013.
2 WHO. International classification of diseases (ICD). 11th edn. Geneva: World Health Organization. 2018.
3 Chamberlain SR, Tiek J, Fontenelle LF, et al. Fractionation of impulsive and compulsive trans-diagnostic phenotypes and their longitudinal associations. Aust N Z J Psychiatry 2019;53:896–907.
4 Tiek J, Oostermane S, Pochazkova L, et al. Overlapping dimensional phenotypes of impulsivity and compulsivity explain co-occurrence of addictive and related behaviors. CNS Spectr 2019;24:426–40.
5 Parkes L, Tiek J, Aquino K, et al. Transdiagnostic variations in impulsivity and compulsivity in obsessive-compulsive disorder and gambling disorder correlate with effective connectivity in cortical-striatal- thalamic-cortical circuits Background : Individual differences in impulsivity and, 2018: 1–45.
6 Chamberlain SR, Stochl J, Redden SA, et al. Latent traits of impulsivity and compulsivity: toward dimensional psychiatry. Psychol Med 2018;48:810–21.
7 Feckzo E, Miranda-Dominguez O, Marr M, et al. The heterogeneity problem: approaches to identify psychiatric subtypes. Trends Cogn Sci 2019;23:584–601.
8 Norman MC. Research Domain Criteria (RDoC) and the DSM—Two Methodological Approaches to Mental Health Diagnosis. JAMA Psychiatry 2015;72:1163–4.
9 Yee CM, Javitt DC, Miller GA. Replacing DSM categorical analyses with dimensional analyses in psychiatry research: the research domain criteria initiative. JAMA Psychiatry 2015;72:1159–60.
10 Van Dam NT, O’Connor D, Marcelle ET, et al. Data-Driven phenotypic categorization for neurobiological analyses: beyond DSM-5 labels. Biol Psychiatry 2017;81:484–94.
11 Den Ouden L, Suo C, Albertella L, et al. Transdiagnostic phenotypes of compulsive behavior and associations with psychological, cognitive, and neurobiological affective processing. Transl Psychiatry 2022:12:10.
12 Zanardi R, Prestifilippo D, Fabbrini C, et al. Precision psychiatry in clinical practice. Int J Psychiatry Clin Pract 2021:25:19–27.
13 Zald DH, Lahey BB. Implications of the hierarchical structure of psychiatric neuroimaging. Biol Psychiatry Cogn Neuroimaging 2017;2:310–7.
14 Holland E, Doernberg E, Shavit R, et al. The cost and impact of compulsivity: a research perspective. Eur Neuropsychopharmacol 2016:26:800–9.
15 Dell’Osso B, Altamura AC, Allen A, et al. Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci 2006:256:464–75.
16 Holland E, Benzaquen SD. Is there a distinct OCD spectrum? CNS Spectr 1996:1:17–26.
17 Fontenelle LF, DestreÀ L, Brierley M-E, et al. The place of obsessive-compulsive and related disorders in the compulsive-impulsive spectrum: a cluster-analytic study. CNS Spectr 2021:1–10.
18 Grant JE, Atmaca M, Fineberg NA, et al. Impulse control disorders and ‘behavioural addictions’ in the ICD-11. World Psychiatry 2014;13:125–7.
19 Luigies J, Lorenzetti V, de Haan S, et al. Defining compulsive behavior. Neuropsychol Rev 2019;29:4–13.
20 Stein DJ, Costa DLC, Lochner C, et al. Obsessive-compulsive disorder. Nat Rev Dis Primers 2019;5.
21 Phillips KA, Stein DJ, Rauch SL, et al. Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V? Depress Anxiety 2010:27:528–55.
22 Bienvenu OJ, Samuels JF, Wuyek LA, et al. Is obsessive-compulsive disorder an anxiety disorder, and what, if any, are specific conditions? A family study perspective. Psychol Med 2012;42:1–13.
23 Holland E, Friedberg JR, Wassermann S. The case for the OCD spectrum. In: Concepts Controv. Obs. Disord. New York, NY, USA: Springer Science + Business Media, 2005: 95–118.
24 Abramowitz JS, Jacoby RJ. Obsessive-Compulsive and related disorders: a critical review of the new diagnostic class. Ann Rev Clin Psychol 2011;15:165–86.
25 Arzeno Ferrão Y, Almeida VP, Bedin NR, et al. Impulsivity and compulsivity in patients with trichotillomania or skin picking compared with patients with obsessive-compulsive disorder. Compr Psychiatry 2006;47:283–9.
26 Grant JE, Peris TS, Ricketts EJ, et al. Reward processing in trichotillomania and skin picking disorder. Brain Imaging Behav 2022;16:547–556.
27 Dally JW, Everitt BJ, Robbins TW. Impulsivity, compulsivity, and top-down cognitive control. Neuron 2011;89:880–94.
28 Castellanos-ryan N, Conrad P. Cognitive risk factors for alcohol and substance addictions. Elsevier Inc, 2020.
29 Goudriaan AE. Integrating Neurocognition from bench to bedside in gambling disorder: from neurocognitive to translational studies. Curr Opin Behav Sci 2020;31:83–84.
30 Kozak K, Lucatch AM, Lowe DJE, et al. The neurobiology of impulsivity and substance use disorders: implications for treatment. Ann N Y Acad Sci 2019;1451:71–91.
31 Robbins TW, Gillan CM, Smith DG, et al. Neurocognitive endophenotypes of impulsivity and compulsivity towards dimensional psychiatry. Trends Cogn Sci 2012;16:81–91.
32 Verdejo-Garcia A, Lawrence AJ, Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev 2008;32:777–810.
33 Potenza MN, Koran LM, Pallanti S. The relationship between impulse-control disorders and obsessive-compulsive disorder: a current understanding and future research directions. Psychiatry Res 2011;170:22–31.
34 Grant JE, Potenza MN, Weinstein A, et al. Introduction to behavioral addictions. Am J Drug Alcohol Abuse 2010;36:233–41.
35 Grassi G, Figee M, Ooms P, et al. Impulsivity and decision-making in obsessive-compulsive disorder after effective deep brain stimulation or treatment as usual. CNS Spectr 2013;18:333–9.
36 Lujten M, Schellekens AF, Kühn S, et al. Disruption of Reward Processing in Addiction : An Image-Based Meta-analysis of
Functional Magnetic Resonance Imaging Studies, *JAMA Psychiatry* 2017;74:387–98.
37 Grassi G, Makris N, Pallant J. Addicted to compulsion: assessing three core dimensions of addiction across obsessive-compulsive disorder and gambling disorder. *Neurosci Biobehav Rev* 2015;35:248–75.
38 van den Heuvel OA, van Wingen G, Soriano-Mas C, et al. Brain circuitry of compulsivity. *Eur Neuropsychopharmacol* 2016;26:810–27.
39 Fontenelle LF, Oostermeijer S, Harrison BJ, et al. Obsessive-Compulsive Disorder, impulsivity, and impulse control disorders and drug addiction. *Drugs* 2011;71:827–40.
40 Prochazkova L, Parkes L, Dawson A, et al. Unpacking the role of self-reported compulsivity and impulsivity in obsessive-compulsive disorder. *CNS Spectr* 2018;23:51–8.
41 Jeffreys-Scott K, Chamberlain SR, Fineberg NA, et al. Cognitive dysfunction in body dysmorphic disorder: new implications for nosological systems and neurobiological models. *CNS Spectr* 2017;22:51–60.
42 Grassi G, Pallant J, Righi L, et al. Think twice: impulsivity and decision making in obsessive-compulsive disorder. *J Behav Addict* 2015;4:263–72.
43 Timpano KR, Rasmussen J, Eemer C, et al. Hoarding and the multi-faceted construct of impulsivity: a cross-cultural investigation. *J Psychiatr Res* 2011;45:367–70.
44 Figue M, Vink M, de Geus F, et al. Dysfunctional reward circuitry in obsessive-compulsive disorder. *Biol Psychiatry* 2011;69:867–74.
45 Cavedini P, Gorzi C, Piccinni M, et al. Executive dysfunctions in obsessive-compulsive patients and unaffected relatives: searching for a new intermediate phenotype. *CNS Spectr* 2010;15:1178–84.
46 Barahona-Corrêa JB, Camacho M, Castro-Rodrigues P, et al. From thought to action: how does the interplay between neurotranscence and phenomenology change our understanding of obsessive-compulsive disorder. *Front Psychol* 2015;6:1798.
47 Figue M, Patti T, Williamson B. Impulsive-compulsive disorder and addictions. *Eur Neuropsychopharmacol* 2016;26:856–68.
48 Chamberlain SR, Solly JE, Hook RW, et al. Cognitive Inflexibility in OCD and related disorders. *Curr Top Behav Neurosci* 2021;49:115–25.
49 Figue M, Luigies J, Goudriaan A. Neurocognitive basis of Compulsivity. In: A Transdiagnostic approach to obsessions, compulsions and related phenomena, 2018: 61–73.
50 Lüscher C, Robbins TW, Everitt BJ. The transition to compulsive in addiction. *Nat Rev Neurosci* 2020;21:247–63.
51 Kashyap H, Fontenelle LF, Miguel EC, et al. Impulsive compulsivity in obsessive-compulsive disorder: a phenotypic marker of patients with poor clinical outcome. *J Psychiatr Res* 2012;46:1146–52.
52 Abramovitch A, McKay D. Behavioral impulsivity in obsessive-compulsive disorder. *J Behav Addict* 2015;6:395–7.
53 Grassi G, Pallant J. Common neural networks between OCD and behavioural addictions: is OCD a behavioral addiction? *Eur psychiatry* 2017;41:521–2.
54 Gillan CM, Papmeyer M, Morein-Zamir S, et al. Disruption in the balance between goal-directed behavior and habit learning in obsessive-compulsive disorder. *Am J Psychiatry* 2011;168:718–26.
55 Everitt BJ, Robbins TW. From the ventral to the dorsal striatum: developing views of their roles in drug addiction. *Neurosci Biobehav Rev* 2013;37:1946–54.
56 Gillan CM, Morein-Zamir S, Urclay GP, et al. Enhanced avoidance habits in obsessive-compulsive disorder. *Biol Psychiatry* 2014;75:831–8.
57 Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. *Nat Neurosci* 2010;13:47;363–70.
58 Fell J, Sheppard D, Fitzgerald PB, et al. Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control. *Neurosci Biobehav Rev* 2010;35:248–75.
59 Sjoerds Z, Luigies J, van den Brink W, et al. The role of habits and motivation in human drug addiction: a reflection. *Front Psychiatry* 2014;5:8.
60 Robbins TW, Clark L. Behavioral addictions. *Curr Opin Neuropsychopharmacol* 2015;30:66–72.
61 Baumeister RF, Nadal AC. Addiction: motivation, action control, and habits of Pleasure. *Motiv Sci* 2017;3:179–95.
62 Fontenelle LF, Oostermeijer S, Ferreira GM, et al. Anticipated reward in obsessive-compulsive disorder: are compulsions rewarding? *J Clin Psychiatry* 2015;76:1134–5.
63 Rotge J-Y, Guelh D, Dhararreguy B, et al. Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. *J Psychiatry Neurosci* 2008;33:405–12.
64 Menezes L, Achard S, Chamberlain SR, et al. Neurocognitive endophenotypes of obsessive-compulsive disorder. *Brain* 2007;130:3223–36.
65 Robbins CMG and TW. Goal-Directed learning and obsessive-compulsive disorder, 2014.
66 Robbins TW, Vagh MM, Banca P. Obsessive-Compulsive disorder: puzzles and prospects. *Neuron* 2019;102:27–47.
67 Ahmari SE, Rauch SL. The prefrontal cortex and OCD. *Eur Neuropsychopharmacology* 2022;47:211–24.
68 Ceceli AO, Bradberry CW, Goldstein RZ. The neurobiology of drug addiction: cross-species insights into the dysfunction and recovery of the prefrontal cortex. *Neuropsychopharmacology* 2019;27:276–91.
69 Piquet-Pessoa M, Fontenelle LF. Opioid antagonists in broadly defined behavioral addictions: a narrative review. *Expert Opin Pharmacother* 2018;17:835–44.
70 Yücel M, Oldenhof E, Ahmed SH, et al. A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study. *Addiction* 2019;114:1095–109.
71 Fontenelle LF, Oldenhof E, Eduard Moreira-de Oliveira M, et al. A transdiagnostic perspective of constructs underlying obsessive-compulsive and related disorders: an international Delphi consensus study. *Aust N Z J Psychiatry* 2020;54:719–31.
72 Yücel M, Lee RSC, Fontenelle LF. A new consensus framework for phenotyping and treatment selecting in addiction and Obsessive-Compulsive-Related disorders. *JAMA Psychiatry* 2021;78:699–700.
73 Cyders MA, Coskunpinar A. Measurement of constructs using self-report and behavioral lab tasks: is there overlap in nomothetic span and construct representation for impulsivity? *Clin Psychol Rev* 2011;31:965–82.
74 Eisenberg IW, Bissett PG, Zeynep Enkavi A, et al. Uncovering the structure of self-regulation through data-driven ontology discovery. *Nat Commun* 2019;10:2319.
75 Rapp AM, Bergman RL, Placentini J, et al. Evidence-Based assessment of Obsessive–Compulsive disorder. *J Cenr Nerv Syst Dis* 2016;8:JCSND.533859.
76 Munn Z, Peters MDJ, Stern C, et al. Systematic review or scoping review? guidance for authors when choosing between a systematic or scoping review approach. *BMJ Med Res Methodol* 2018;18:143.
77 Arksey H, O’Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005;8:19–32.
78 Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Synth* 2020;18:2119–26.
79 Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018;169:467–73.
80 Peters MDJ, Godfrey C, McNerney P. Chapter 11: scoping reviews (2020 version). In: *JBI man Evid Synth*. JBI, 2020.
Subjective Assessment of Research Domain Criteria constructs in addiction and compulsive disorders: a scoping review protocol

Ana Paula Ribeiro, Marcelo Piquet-Pessôa, Carina Félix-da-Silva, Julia E. Mühlbauer, Juliana B de-Salles-Andrade, Leonardo F Fontenelle

Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

| SECTION         | ITEM | PRISMA-ScR CHECKLIST ITEM                                                                 | REPORTED ON PAGE # |
|-----------------|------|------------------------------------------------------------------------------------------|--------------------|
| TITLE           |      |                                                                                          |                    |
| Title           | 1    | Identify the report as a scoping review.                                                  | 1                  |
| ABSTRACT        |      |                                                                                          |                    |
| Structured summary | 2  | Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives. | 1                  |
| INTRODUCTION    |      |                                                                                          |                    |
| Rationale       | 3    | Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach. | 4                  |
| Objectives      | 4    | Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives. | 5                  |
| METHODS         |      |                                                                                          |                    |
| Protocol and registration | 5  | Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number. | OSF Registration DOI [10.17605/OSF.IO/UJ7G5] |
| Eligibility criteria | 6  | Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale. | 9 and 10 (Tables 2 and 4). |
| Information sources* | 7  | Describe all information sources in the search (e.g., databases)                          | 8                  |
| SECTION                          | ITEM | PRISMA-ScR CHECKLIST ITEM                                                                 | REPORTED ON PAGE # |
|---------------------------------|------|------------------------------------------------------------------------------------------|--------------------|
| Search                          | 8    | Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated. | 9                  |
| Selection of sources of evidence† | 9    | State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review. | 9                  |
| Data charting process‡          | 10   | Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators. | 10 (Table 5 - Data Extraction Template) |
| Data items                      | 11   | List and define all variables for which data were sought and any assumptions and simplifications made. | NA                 |
| Critical appraisal of individual sources of evidence§ | 12   | If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate). | NA                 |
| Synthesis of results            | 13   | Describe the methods of handling and summarizing the data that were charted. | NA                 |

**RESULTS**

| SECTION                          | ITEM | PRISMA-ScR CHECKLIST ITEM                                                                 | REPORTED ON PAGE # |
|---------------------------------|------|------------------------------------------------------------------------------------------|--------------------|
| Selection of sources of evidence | 14   | Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram. | NA                 |
| Characteristics of sources of evidence | 15   | For each source of evidence, present characteristics for which data were charted and provide the citations. | NA                 |
| Critical appraisal within sources of evidence | 16   | If done, present data on critical appraisal of included sources of evidence (see item 12). | NA                 |
| Results of individual sources of | 17   | For each included source of evidence, present the relevant data that were charted that relate | NA                 |
| SECTION               | ITEM | PRISMA-ScR CHECKLIST ITEM                                                                 | REPORTED ON PAGE # |
|----------------------|------|------------------------------------------------------------------------------------------|--------------------|
| evidence             |      | to the review questions and objectives.                                                   |                    |
| Synthesis of results | 18   | Summarize and/or present the charting results as they relate to the review questions and objectives. | NA                 |
| DISCUSSION           |      |                                                                                            |                    |
| Summary of evidence  | 19   | Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups. | NA                 |
| Limitations          | 20   | Discuss the limitations of the scoping review process.                                     | NA                 |
| Conclusions          | 21   | Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps. | NA                 |
| FUNDING              |      |                                                                                            |                    |
| Funding              | 22   | Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review. | L.F.F. is supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (#302526/2018-8), Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (#E 26/203.052/2017), the D’Or Institute of Research and Education (no grant number) and the David Winston Turner Endowment Fund (no grant number). None of the above funding bodies were involved in the study design, management, data analysis and interpretation of results, or writing of the manuscript. |

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.
* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.
† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with information sources (see first footnote).
‡ The frameworks by Arksey and O’Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.
§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–473. doi: 10.7326/M18-0850.
Subjective Assessment of Research Domain Criteria constructs in addiction and compulsive disorders: a scoping review protocol
Ana Paula Ribeiro, Marcelo Piquet-Pessôa, Carina Félix-da-Silva, Julia E. Mühlbauer, Juliana B de-Salles-Andrade, Leonardo F Fontenelle

Search Strategies for all databases

Ovid MEDLINE 1946 to November Week 2 2021
**Advanced search** (Title, Abstract, Keywords)

| # | Searches |
|---|---|
| 1 | (response inhibition OR habit* OR compuls* OR reward OR action selection OR performance monitoring). ti,ab,kw. |
| 2 | (self-report OR questionnaire OR psychometric OR scale OR measurement tool* OR interview* OR index OR instrument). ti,ab,kw. |
| 3 | (valid* OR reliab*). ti,ab,kw. |
| 4 | 1 AND 2 AND 3 |

EMBASE

**Advanced search** (Title, Abstract, Keywords)

| # | Searches |
|---|---|
| 1 | (‘response inhibition’ OR habit* OR compuls* OR reward OR ‘action selection’ OR ‘performance monitoring’):ti,ab,kw |
| 2 | (self-report OR questionnaire OR psychometric OR scale OR ‘measurement tool*’ OR interview* OR index OR instrument):ti,ab,kw |
| 3 | (valid* OR reliab*):ti,ab,kw |
| 4 | 1 AND 2 AND 3 |

PsycINFO

**Advanced search** (Title, Abstract, Keywords)

| # | Searches |
|---|---|
| 1 | Title: (‘response inhibition’ OR habit* OR compuls* OR reward OR ‘action selection’ OR ‘performance monitoring’) AND (self-report OR questionnaire OR psychometric OR scale OR ‘measurement tool*’ OR interview* OR index OR instrument) AND (valid* OR reliab*) |
| 2 | Abstract: (‘response inhibition’ OR habit* OR compuls* OR reward OR ‘action selection’ OR ‘performance monitoring’) AND (self-report OR questionnaire OR psychometric OR scale OR ‘measurement tool*’ OR interview* OR index OR instrument) AND (valid* OR reliab*) |
| 3 | Keywords: (‘response inhibition’ OR habit* OR compuls* OR reward OR ‘action selection’ OR ‘performance monitoring’) AND (self-report OR questionnaire OR psychometric OR scale OR ‘measurement tool*’ OR interview* OR index OR instrument) AND (valid* OR reliab*) |
| 4 | 1 OR 2 OR 3 |
## WEB OF SCIENCE
### Advanced search (Title, Abstract, Keywords)

| # | Searches |
|---|---------|
| 1 | TI=((‘response inhibition’ OR habit* OR compuls* OR reward OR ‘action selection’ OR ‘performance monitoring’) AND (self-report OR questionnaire OR psychometric OR scale OR ‘measurement tool*’ OR interview* OR index OR instrument)) |
| 2 | AB=((‘response inhibition’ OR habit* OR compuls* OR reward OR ‘action selection’ OR ‘performance monitoring’) AND (self-report OR questionnaire OR psychometric OR scale OR ‘measurement tool*’ OR interview* OR index OR instrument)) |
| 3 | AK=((‘response inhibition’ OR habit* OR compuls* OR reward OR ‘action selection’ OR ‘performance monitoring’) AND (self-report OR questionnaire OR psychometric OR scale OR ‘measurement tool*’ OR interview* OR index OR instrument) AND (valid* OR reliab*)) |
| 4 | 1 OR 2 OR 3 |